Search This Blog

Tuesday, November 29, 2022

UK regulator says reactions in eye from Sanofi drug must be quickly reviewed

 

Britain's medicines regulator said on Tuesday that any new or worsening reactions in patients' eyes arising from use of Sanofi's best-selling drug Dupixent should be promptly reviewed by healthcare professionals.

The UK's Medicines and Healthcare products Regulatory Agency said most ocular reactions seen with the drug are mild and can be managed.

https://www.marketscreener.com/quote/stock/SANOFI-4698/news/UK-regulator-says-reactions-in-eye-from-Sanofi-drug-must-be-quickly-reviewed-42429039/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.